 |
10 Diseases |  |
0 Trials |
|
0 Trials |  |
43 News |  |
- | Bekinda (ondansetron controlled-release) / RedHill
Brilliant 👏🏻 🔴⚪️⚫️ #GlazersOut #FullSaleOnly #NoToIneos #MUFC_FAMILY #BeKindAlways (Twitter) - Apr 30, 2023
- || Bekinda (ondansetron controlled-release) / RedHill
I am with you,Dr. 👍,💯% ,on all 3. It only takes a moment for Life to change upside down. We have experienced that. I'm living every moment now. Nothing should be put off for later 🙏 I am Thankful for you 🙏 cause I learn a lot from you and Greg ❤️❤️ #LIVENOW #BeKindAlways (Twitter) - Mar 20, 2023
- || Bekinda (ondansetron controlled-release) / RedHill
👏👏👏👏 Thank a Resident by taking action to ensure they survive 🧠😵💫 during training … & beyond #BeKindAlways #payitforward (Twitter) - Feb 24, 2023
- || Bekinda (ondansetron controlled-release) / RedHill
Happy New Year to all my friends and followers and everyone in between. Here’s hoping for a better 2023. I wish you health, happiness, fulfillment and the ability to be true to yourself. #BeKindAlways #odotherightthing #helpinghand #HappyNewYear2023 (Twitter) - Dec 31, 2022
- |||| Bekinda (ondansetron controlled-release) / RedHill
Clinical: WHAT AN IMAGE! #CovidIsNotOver #COVID19 #VaccinesWork #VaccinesSaveLives #GetBoosted #MaskUp #BeKindAlways #Titanic #iceberg #AHead @CDCgov @CDCDirector @CDCGlobal @WHO @NIH @NIHDirector @drsanjaygupta @PeterHotez @WHCOVIDResponse @Laurie_Garrett @KDHE (Twitter) - May 21, 2022
- || Bekinda (ondansetron controlled-release) / RedHill
All of “disappointments”along my journey taught me important life lessons #gratitude #educationiskey #friendship #family ❤️🌈😎🦋 #BeKindAlways @nakhtermd @AkhilNarangMD @docbfreed @ALewisMD @WilcoxHeart @NMHheartdoc @RigolinVera (Twitter) - Apr 21, 2022
- || Bekinda (ondansetron controlled-release) / RedHill
#puckdogecoin @dogecoin go to #skisshool #boobs @greengodict @urbandictionary @CambridgeWords @MacDictionary @readingrainbow @betterworldbook #bekindtoeachother #bekindalways #haveasenseofhumour @CandidDotOrg #GenuineQuestion @EricRWeinstein @edgeonline #ALIENWARE #LoveTwitter (Twitter) - Jul 9, 2021
- || Bekinda (ondansetron controlled-release) / RedHill
#bekindalways (Twitter) - Jun 26, 2021
- | Bekinda (ondansetron controlled-release) / RedHill
Journal: Absence of QT prolongation after administration of a 24-mg bimodal-release ondansetron pill (RHB-102). (Pubmed Central) - Jun 22, 2021
In patients with normal baseline QTc, 24-mg bimodal-release ondansetron did not prolong the QTc in comparison to placebo.
- | Bekinda (ondansetron controlled-release) / RedHill
Journal: Update on nonantibiotic therapies for acute gastroenteritis. (Pubmed Central) - Jun 2, 2021
Optimization of the real-life effectiveness of this therapy will require implementation strategies. Recent high-quality evidence showing a lack of efficacy and potential harm associated with probiotic use suggests that routine use for AGE should be discouraged.
- Bekinda (ondansetron controlled-release) / RedHill, Mesupron (upamostat) / RedHill, Yeliva (opaganib) / RedHill
[VIRTUAL] RedHill Biopharma () - Jun 9, 2020 - Abstract #BIO2020BIO_450;
RedHill’s key clinical late-stage development programs include: RHB-104, RHB-204, RHB-102 (Bekinda®), ABC294640 (Yeliva®), RHB-106 and RHB-107. More information about the Company is available at www.redhillbio.com.
- |||| Bekinda (ondansetron controlled-release) / RedHill
Trial completion: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) (clinicaltrials.gov) - Jan 17, 2018
P2, N=120, Completed, Sponsor: RedHill Biopharma Limited
More information about the Company is available at www.redhillbio.com. Active, not recruiting --> Completed
- ||||||| Bekinda (ondansetron controlled-release) / RedHill
Trial completion, Trial primary completion date: GUARD: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (clinicaltrials.gov) - Oct 6, 2017
P3, N=330, Completed, Sponsor: RedHill Biopharma Limited
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> Feb 2017
- ||| Bekinda (ondansetron controlled-release) / RedHill
Enrollment closed: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) (clinicaltrials.gov) - Jun 7, 2017
P2, N=120, Active, not recruiting, Sponsor: RedHill Biopharma Limited
Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> Feb 2017 Recruiting --> Active, not recruiting
- ||||| Bekinda (ondansetron controlled-release) / RedHill
Enrollment closed: GUARD: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (clinicaltrials.gov) - Feb 14, 2017
P3, N=320, Active, not recruiting, Sponsor: RedHill Biopharma Limited
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Bekinda (ondansetron controlled-release) / RedHill
Trial primary completion date: GUARD: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (clinicaltrials.gov) - Nov 23, 2016
P3, N=320, Recruiting, Sponsor: RedHill Biopharma Limited
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Jul 2017
- |||| Bekinda (ondansetron controlled-release) / RedHill
Enrollment open: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) (clinicaltrials.gov) - May 28, 2016
P2, N=120, Recruiting, Sponsor: RedHill Biopharma Limited
Trial primary completion date: Dec 2016 --> Jul 2017 Not yet recruiting --> Recruiting
- ||||| Bekinda (ondansetron controlled-release) / RedHill
New P2 trial: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) (clinicaltrials.gov) - May 2, 2016
P2, N=120, Not yet recruiting, Sponsor: RedHill Biopharma Limited
- |||| Bekinda (ondansetron controlled-release) / RedHill
Trial primary completion date: GUARD: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (clinicaltrials.gov) - Apr 14, 2016
P3, N=320, Recruiting, Sponsor: RedHill Biopharma Limited
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Dec 2016
- |||| Bekinda (ondansetron controlled-release) / RedHill
Trial primary completion date: GUARD: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (clinicaltrials.gov) - Oct 23, 2015
P3, N=320, Recruiting, Sponsor: RedHill Biopharma Limited
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- |||| Bekinda (ondansetron controlled-release) / RedHill
Trial primary completion date: GUARD: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (clinicaltrials.gov) - Mar 11, 2015
P3, N=320, Recruiting, Sponsor: RedHill Biopharma Limited
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Mar 2015 --> Dec 2015
- |||||| Bekinda (ondansetron controlled-release) / RedHill
Enrollment open: GUARD: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (clinicaltrials.gov) - Nov 25, 2014
P3, N=320, Recruiting, Sponsor: RedHill Biopharma Limited
Trial primary completion date: Mar 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- |||||||||| Bekinda (ondansetron controlled-release) / RedHill
New P3 trial: GUARD: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (clinicaltrials.gov) - Sep 22, 2014
P3, N=320, Not yet recruiting, Sponsor: RedHill Biopharma Limited